Trending >

BioSyent Keeps Momentum Going with Solid Q2 Earnings

BioSyent (TSXV:RX) today announced Q2 results that are indicative of the revenue and earnings momentum investors have to come to expect from this emerging specialty pharma company based in Ontario. As I have written previously in Cantech, I believe BioSyent is carving a path that is very similar to another Canadian specialty pharma success story – Paladin Labs.

The numbers reported by BioSyent are resoundingly positive, with double-digit growth rates, versus the previous quarter, across the top and bottom lines. The company reported quarterly net income of $889,000, or 6 cents per fully diluted share, on $$3.07-million of sales. For the first half of 2014, the company has earned $1.4 million after taxes, or 10 cents per fully diluted share, on total sales of $5.5 million. When compared to the first half of 2013, the 2014 results represent 66% top-line growth and 84% bottom-line growth.

At its current $120 million market cap, BioSyent investors are banking on continued growth for the coming quarters. Candidly, why shouldn’t they? Over the past three years the company has a 68% compound annual growth rate for its top-line. Even if the pace of growth slows for their existing portfolio of pharmaceutical products in Canada, they have a series of new products ready to be launched.

The company recently received Health Canada approval for an urgent care product that they aim to launch sometime in the next 3-6 months. They have also guided that they will launch a new gastrointestinal product sometime before year-end. Combine these two, soon to be launched, products with the company’s June 2014 launch of a new women’s health product, RepaGyn, and it appear that BioSyent has the right formula of existing and new products to maintain its financial momentum and investor interest.


We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

insta twitter facebook


Leave a Reply